Search This Blog

Tuesday, August 6, 2019

Walgreens to close about 200 stores in US

 Walgreens Boots Alliance Inc said on Tuesday it plans to close about 200 U.S. stores and expects to record related pre-tax charges of between $1.9 billion and $2.4 billion.

The Deerfield, Illinois-based company in June said it would close about 200 stores in the United Kingdom as performance in its UK Boots business continued to lag in the latest reported quarter.
The store closures are part of the company’s cost management program that is aimed at mitigating the pressure related to generic drug prices, the company had said in June.
The program is expected to deliver annual cost savings in excess of $1.5 billion by 2022, the company said in a regulatory filing https://bit.ly/2YJYG6U on Tuesday.

Nu Skin EPS misses by $0.01, beats on revenue

Nu Skin (NYSE:NUS): Q2 GAAP EPS of $0.83 misses by $0.01.
Revenue of $623.5M (-11.5% Y/Y) beats by $1.18M.

Omega Healthcare 2019 FFO guidance disappoints

Omega Healthcare Investors (NYSE:OHI) slips 0.8% in after-hours trading after its revised 2019 adjusted FFO per share guidance to $3.03-$3.07 trails consensus estimate of $3.08.
Compares with prior range of $3.00-$3.12.
Sees Q4 adjusted FFO per share of 76 cents-79 cents vs. prior range of 78 cents-81 cents; consensus estimate is 79 cents.
“We have tightened our 2019 year-end guidance and adjusted our fourth-quarter guidance primarily as a result of the pending sale of ten Diversicare assets, continuing Daybreak on a cash basis at approximately $3M to $5M per quarter and to a lesser extent, shares issued under our equity programs,” said CFO Bob Stephenson.
As previously stated, plans to continue issuing equity under its at-the-market program to further de-lever, which may significantly impact guidance.
Q2 adjusted FFO per share of 77 cents beats the average analyst estimate of 76 cents and rose from 76 cents in the year-ago quarter. Adjusted FFO totaled $169.2M vs. $159.1M a year ago.
During Q3 agreed to acquire $735M of skilled nursing and assisted living facilities.
Doesn’t see Daybreak reverting to contractual rent for the foreseeable future and is working with Daybreak management and third-party consultants to maximize Daybreak cash flows.
Conference call on Aug. 7 at 11:00 AM ET.

Jazz Pharmaceuticals EPS beats by $0.48, beats on revenue

Jazz Pharmaceuticals (NASDAQ:JAZZ): Q2 Non-GAAP EPS of $4.05 beats by $0.48; GAAP EPS of $4.45 beats by $3.73.
Revenue of $534.13M (+6.7% Y/Y) beats by $26.9M.
Shares +0.5%.

Enanta Pharma EPS beats by $0.19, misses on revenue

Enanta Pharma (NASDAQ:ENTA): Q3 GAAP EPS of $0.33 beats by $0.19.
Revenue of $44.4M (-22.5% Y/Y) misses by $2.58M.

Retrophin EPS misses by $0.18, beats on revenue

Retrophin (NASDAQ:RTRX): Q2 Non-GAAP EPS of -$0.58 misses by $0.18; GAAP EPS of -$0.92 misses by $0.28.
Revenue of $44.7M (+8.2% Y/Y) beats by $1.69M.

Alder Bio EPS beats by $0.22

Alder Bio (NASDAQ:ALDR): Q2 GAAP EPS of -$0.72 beats by $0.22.
Cash, equivalents, investments and restricted cash of $440.65M.